5T4: a delicate target for sophisticated payload delivery – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of the free report Pipeline of 5T4-Targeted Immunotherapies to showcase its newest service of pipeline reviews. The free report reviews the pipeline of active anti-5T4...

B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-B7-H4 immunotherapeutics in R&D: Pipeline of B7-H4-Targeted Immunotherapies. This competitive intelligence report about B7-H4-Targeted Immunotherapies...

Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-mesothelin immunotherapeutics in R&D: Pipeline of Mesothelin-Targeted Immunotherapies. This competitive intelligence report...

c-Met: a well-suited target for payload delivery by antibodies – a pipeline review STUTTGART, Germany I August 15, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-c-Met immunotherapeutics in R&D: Pipeline of c-Met-Targeted Immunotherapies. This competitive intelligence report about c-Met-Targeted...

STUTTGART, Germany I August 14, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of drug modality technologies available for a R&D organization. La Merie Publishing has released a new service offering which evaluates customer-selected targets...

STUTTGART, Germany I August 14, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Her3 immunotherapeutics in R&D: Pipeline of Her3-Targeted Immunotherapies. This competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research...

DLL3: competitors of clinically validated target develop effector-enhanced next generation product candidates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis. DLL3 is a clinically validated target for treatment of small cell lung cancer which recently started commercialization. Delta-like...

TSLP (thymic stromal lymphoprotein) is a clinically and commercially validated inflammatory target attracting numerous competitors STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: TSLP Inhibitors and TSLP Receptor Antagonists: a Competitor Analysis TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as...

TL1A (TNF-like ligand 1A): the next big, clinically validated target for inflammatory bowel disease STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis TL1A as a target for mainly inflammatory bowel disease recently has received great...

Folate Receptor alpha: a clinically validated target for ovarian cancer with commercial potential and a decent competitive environment STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor Analysis Folate receptor alpha (FRα) is a cell surface...